These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21481829)

  • 21. Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator.
    Gardiwal A; Yu H; Oswald H; Luesebrink U; Ludwig A; Pichlmaier AM; Drexler H; Klein G
    Europace; 2008 Mar; 10(3):358-63. PubMed ID: 18308756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of beta-blockers in patients with an implantable cardioverter defibrillator.
    LaPointe NM; Stafford JA; Pappas PA; Al-Khatib SM; Anstrom KJ
    Ann Pharmacother; 2009 Jul; 43(7):1189-96. PubMed ID: 19567655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter, prospective, randomized safety and efficacy study of a new atrial-based managed ventricular pacing mode (MVP) in dual chamber ICDs.
    Sweeney MO; Ellenbogen KA; Casavant D; Betzold R; Sheldon T; Tang F; Mueller M; Lingle J;
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):811-7. PubMed ID: 16101620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of dual chamber pacing on the incidence of atrial and ventricular tachyarrhythmias in recipients of implantable cardioverter defibrillators.
    Strohmer B; Mermi J; Castellanos E; Mayr H; Gill J; Abadia AA; Kuehl M; Wolpert C
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S249-54. PubMed ID: 15683508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia.
    Glikson M; Lipchenca I; Viskin S; Ballman KV; Trusty JM; Gurevitz OT; Luria DM; Eldar M; Hammill SC; Friedman PA
    J Cardiovasc Electrophysiol; 2004 Jun; 15(6):658-64. PubMed ID: 15175060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 1+1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias.
    Bänsch D; Steffgen F; Grönefeld G; Wolpert C; Böcker D; Mletzko RU; Schöls W; Seidl K; Piel M; Ouyang F; Hohnloser SH; Kuck KH
    Circulation; 2004 Aug; 110(9):1022-9. PubMed ID: 15326069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II.
    Steinberg JS; Fischer A; Wang P; Schuger C; Daubert J; McNitt S; Andrews M; Brown M; Hall WJ; Zareba W; Moss AJ;
    J Cardiovasc Electrophysiol; 2005 Apr; 16(4):359-65. PubMed ID: 15828875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
    Corrado D; Calkins H; Link MS; Leoni L; Favale S; Bevilacqua M; Basso C; Ward D; Boriani G; Ricci R; Piccini JP; Dalal D; Santini M; Buja G; Iliceto S; Estes NA; Wichter T; McKenna WJ; Thiene G; Marcus FI
    Circulation; 2010 Sep; 122(12):1144-52. PubMed ID: 20823389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heart rate predicts outcomes in an implantable cardioverter-defibrillator population.
    Ahmadi-Kashani M; Kessler DJ; Day J; Bunch TJ; Stolen KQ; Brown S; Sbaity S; Olshansky B;
    Circulation; 2009 Nov; 120(21):2040-5. PubMed ID: 19901194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indications for dual-chamber cardioverter defibrillators at implant and at 1 year follow-up: a retrospective analysis in the single-chamber defibrillator era.
    Proclemer A; Della Bella P; Facchin D; Fattore L; Carbucicchio C; Tondo C; Lunati M; Vecchi MR; Petz E; Zecchin M
    Europace; 2001 Apr; 3(2):132-5. PubMed ID: 11333050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies.
    Verma A; Kilicaslan F; Martin DO; Minor S; Starling R; Marrouche NF; Almahammed S; Wazni OM; Duggal S; Zuzek R; Yamaji H; Cummings J; Chung MK; Tchou PJ; Natale A
    Heart; 2006 Feb; 92(2):190-5. PubMed ID: 15923278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy.
    Grimm W; Plachta E; Maisch B
    Pacing Clin Electrophysiol; 2006 Jul; 29(7):759-64. PubMed ID: 16884513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design.
    Raviele A; Bongiorni MG; Brignole M; Cappato R; Capucci A; Gaita F; Mangiameli S; Montenero A; Pedretti R; Salerno J; Sermasi S
    Am J Cardiol; 1999 Mar; 83(5B):104D-111D. PubMed ID: 10089851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-blocker therapy is not associated with symptoms of depression and anxiety in patients receiving an implantable cardioverter-defibrillator.
    Hoogwegt MT; Kupper N; Theuns DA; Jordaens L; Pedersen SS
    Europace; 2012 Jan; 14(1):74-80. PubMed ID: 21920910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-blocker therapy is associated with a lower incidence of syncope due to fast ventricular tachycardias among implantable cardioverter-defibrillator patients with left ventricular dysfunction: results from a multicenter study.
    Jiménez-Candil J; Anguera I; Durán O; Hernández J; Fernández-Portales J; Moríñigo JL; Martín A; Dallaglio P; Bravo L; di Marco A; Sánchez PL
    J Interv Card Electrophysiol; 2018 Jun; 52(1):69-76. PubMed ID: 29557531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implantable cardioverter defibrillator does not cure the heart.
    Sławuta A; Boczar K; Ząbek A; Gajek J; Lelakowski J; Vijayaraman P; Małecka B
    Pol Merkur Lekarski; 2018 Jan; 44(259):23-25. PubMed ID: 29374419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy.
    Rankovic V; Karha J; Passman R; Kadish AH; Goldberger JJ
    Am J Cardiol; 2002 May; 89(9):1072-6. PubMed ID: 11988198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.